UB Paderborn / Katalog / Suche / in CDI

Selexipag for the Treatment of Pulmonary Arterial Hypertension

The New England journal of medicine, 2015-12, Vol.373 (26), p.2522-2533

2015

Link zum Volltext

Verfügbarkeit prüfen

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

The European respiratory journal, 2017-08, Vol.50 (2), p.1602493-1602493

2017

Link zum Volltext

Verfügbarkeit prüfen

P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study

The American journal of gastroenterology, 2021-12, Vol.116 (Suppl 1), p.S11-S11

2021

Link zum Volltext

Verfügbarkeit prüfen

Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines

Arthritis & rheumatology (Hoboken, N.J.), 2024-05, Vol.76 (5), p.777-782

2024

Link zum Volltext

Verfügbarkeit prüfen

An approach to confirmatory testing of subpopulations in clinical trials

Biometrical journal, 2015-09, Vol.57 (5), p.897-913

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Clinical cancer research, 2008-05, Vol.14 (9), p.2717-2725

2008

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)

Journal of thoracic oncology, 2009-11, Vol.4 (11), p.1357-1363

2009

Link zum Volltext

Verfügbarkeit prüfen

Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. J. Clin. Med. 2022, 11 , 6189

Journal of clinical medicine, 2023-06, Vol.12 (12), p.3939

2023

Link zum Volltext

Verfügbarkeit prüfen

Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension

Journal of clinical medicine, 2022-10, Vol.11 (20), p.6189

2022

Link zum Volltext

Verfügbarkeit prüfen

Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): A phenotypic comparison

Atherosclerosis, 2006-10, Vol.188 (2), p.398-405

2006

Link zum Volltext

Verfügbarkeit prüfen

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Circulation (New York, N.Y.), 2019-05, Vol.139 (21), p.2440-2450

2019

Link zum Volltext

Verfügbarkeit prüfen

Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study

Advances in therapy, 2022-09, Vol.39 (9), p.4346-4358

2022

Link zum Volltext

Verfügbarkeit prüfen

Performance of DETECT PAH algorithm according to the hemodynamic definition of pulmonary arterial hypertension (PAH) in the 2022 ESC/ERS guidelines: Early detection of pulmonary arterial hypertension in systemic sclerosis patients

Arthritis & rheumatology (Hoboken, N.J.), 2023-12

2023

Link zum Volltext

Verfügbarkeit prüfen

Erratum note to 'Time-to-event analysis with treatment arm selection at interim'

Statistics in medicine, 2013-05, Vol.32 (11), p.1974-1974

2013

Link zum Volltext

Verfügbarkeit prüfen

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

International journal of chronic obstructive pulmonary disease, 2012-01, Vol.7 (default), p.503-513

2012

Link zum Volltext

Verfügbarkeit prüfen

Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients

Respiratory medicine, 2011-03, Vol.105 (3), p.337-342

2011

Link zum Volltext

Verfügbarkeit prüfen

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018-02, Vol.18 (1), p.37-47

2018

Link zum Volltext

Verfügbarkeit prüfen

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study

The Journal of heart and lung transplantation, 2020-04, Vol.39 (4), p.300-309

2020

Link zum Volltext

Verfügbarkeit prüfen

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

European journal of heart failure, 2019-03, Vol.21 (3), p.352-359

2019

Link zum Volltext

Verfügbarkeit prüfen

P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study

The American journal of gastroenterology, 2021-12, Vol.116 (Suppl 1), p.S11

2021

Link zum Volltext

Verfügbarkeit prüfen

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension

Circulation (New York, N.Y.), 2019-05, Vol.139 (21), p.2440-2450

2019

Link zum Volltext

Verfügbarkeit prüfen

Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. IJ. Clin. Med./I B2022/B, I11/I, 6189

Journal of clinical medicine, 2023-06, Vol.12 (12)

2023

Link zum Volltext

Verfügbarkeit prüfen

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study

The Journal of heart and lung transplantation, 2018-03, Vol.37 (3), p.401-408

2018

Link zum Volltext

Verfügbarkeit prüfen

Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model

Journal of thoracic oncology, 2011-12, Vol.6 (12), p.2120-2129

2011

Link zum Volltext

Verfügbarkeit prüfen

Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH)

Chest, 2015-10, Vol.148 (4), p.961A-961C

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study

Performance of DETECT Pulmonary Arterial Hypertension Algorithm According to the Hemodynamic Definition of Pulmonary Arterial Hypertension in the 2022 European Society of Cardiology and the European Respiratory Society Guidelines

An approach to confirmatory testing of subpopulations in clinical trials

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)

Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. J. Clin. Med. 2022, 11 , 6189

Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension

Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): A phenotypic comparison

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study

Performance of DETECT PAH algorithm according to the hemodynamic definition of pulmonary arterial hypertension (PAH) in the 2022 ESC/ERS guidelines: Early detection of pulmonary arterial hypertension in systemic sclerosis patients

Erratum note to 'Time-to-event analysis with treatment arm selection at interim'

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial

Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

P043 Resource Utilization and Productivity Loss among Patients with Inflammatory Bowel Disease in Sweden: A Longitudinal Nationwide Population-based Study

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension

Correction: Jansa et al. Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension. IJ. Clin. Med./I B2022/B, I11/I, 6189

Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study

Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model

Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH)

Suchergebnisse filtern